European public and private organisations, including Intravacc, are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.
For more information and full press release, follow link
‘Will all laboratory animals be retired in 2040?’
Replacing, reducing and refining the use animals in the lab…. Throughout his career Prof. Dr. Coenraad Hendriksen worked on all aspects of the 3Rs, particularly in the vaccine field, and successfully developed variety of alternatives.
With her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March.